Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404963 · ClinicalTrials.gov registry record · Phase 1
A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT00404963 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 72 participants.
The verdict
NCT00404963, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study represents the first administration of GSK376501 in humans and the goal is to evaluate its initial safety and tolerability. The way the human body processes GSK376501 will also be determined.
Interventions
- DRUG placebo
- DRUG GSK376501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00404963
The ClinicalTrials.gov registry entry for NCT00404963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00404963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00404963 about?
NCT00404963 is a clinical study titled "A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects". This study represents the first administration of GSK376501 in humans and the goal is to evaluate its initial safety and tolerability. The way the human body processes GSK376501 will also be determined.
What is the current status of trial NCT00404963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2006-10. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00404963?
The interventions under investigation include: placebo (DRUG), GSK376501 (DRUG).
Who is sponsoring clinical trial NCT00404963?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.